ArticleStem cell research & therapy2026
SDF-1 loaded dECM patch improves cardiac function in rats after myocardial ischemia.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIschemic heart disease (IHD) remains a global health challenge, characterized by irreversible cardiomyocyte loss and pathological ventricular remodeling. Myocardial patches provide mechanical support for infarcted myocardium, but conventional biomaterials lack bioactive components to facilitate tissue regeneration. This study introduces a novel therapeutic strategy: a stromal cell-derived factor-1 (SDF-1)-loaded decellularized extracellular matrix (dECM) (SDF-dECM) patch addressing both biological and biomechanical deficiencies in myocardial repair.
methodsPorcine left ventricular dECM was decellularized, and SDF-1 was loaded to fabricate the SDF-dECM patch. The patch's physicochemical properties, biocompatibility, and SDF-1 release profile were evaluated via hematoxylin and eosin/4',6-diamidino-2-phenylindole staining, scanning electron microscopy, cytotoxicity assay, and enzyme-linked immunosorbent assay (ELISA). Transwell assays determined the chemotactic effect of SDF-1 on bone marrow mesenchymal stem cells (BMMSCs) and optimal concentration. Uniaxial tensile testing assessed mechanical properties. A finite element method (FEM) model was established to evaluate the patch's mechanical support. In vivo, male Sprague-Dawley rats were randomly divided into four groups (n = 15 per group): Sham, myocardial infarction (MI), MI + dECM, and MI + SDF-dECM. Echocardiography, histochemical staining, and immunofluorescence staining were used to assess cardiac function, tissue morphology, BMMSCs homing, microvascular regeneration, and cardiomyocyte apoptosis. The paracrine mechanism of BMMSCs was evaluated via ELISA and functional assays.
resultsThe SDF-dECM patch achieved successful decellularization, maintained a porous structure (50-150 μm pore size), exhibited favorable biphasic mechanical properties, and exhibited sustained SDF-1 release for 28 days. SDF-1 effectively induced BMMSCs migration via the SDF-1/CXCR4 axis, with 200 ng/mL as the optimal concentration. In vivo, the SDF-dECM patch significantly enhanced endogenous BMMSCs homing to the peri-infarct area, promoted peri-infarct microvascular regeneration, and inhibited cardiomyocyte apoptosis. BMMSCs-conditioned medium contained high levels of vascular endothelial growth factor and hepatocyte growth factor, exerting pro-angiogenic and anti-apoptotic effects. FEM simulations showed the patch reduced infarct zone wall stress and stress concentration. Echocardiography and histological analysis confirmed the SDF-dECM patch significantly improved cardiac function, reduced infarct size and alleviated myocardial fibrosis.
conclusionThe dual-functional SDF-dECM patch integrates sustained SDF-1 delivery for endogenous BMMSCs mobilization and biomechanical support to mitigate ventricular remodeling. The synergy between biological activity and mechanical stabilization provides a promising therapeutic strategy for IHD, overcoming limitations of conventional biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.